This year continues to be a tough one for the lab industry, with the G-2 Laboratory Stock Index down 7% over the last five weeks for the week ended Feb. 22, 2008. But February wasn’t unkind to all the publicly traded laboratories, many of whom released fourth quarter and full year 2007 results last month. For instance, LabCorp (Burlington, NC) was up 8% to $79.29 per share for a market cap of $9.1 billion over the past four weeks for the week ended Feb. 22, 2008. Another company, Monogram Biosciences (South San Francisco, CA) was up 19% to $1.46 per share for a market cap of $193 million for the same time period.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

March 2008 - Table of Contents

LIR March 2008 (full PDF issue)

More Labs Turn to Alternative Competitive Strategies as Contract Prices Decline

Quest Projects 9% Growth in 2008 Revenues, LabCorp Sees 13%

Physicians Name Insurance, Billing Woes as Top Nat’l Lab Complaints

Benchmarking the National Labs—Quest and LabCorp Post Gains in Revenue per FTE

As Managed Care Upheavals Subside, It’s Time for Labs to Strategize

San Diego Labs Hope for Injunction to Halt Comp Bidding Demo

Symbion Deal Consolidates Australia’s Pathology Market

As Quest Boosts Sales Efforts, Here’s How to Compete

Lab Index Down 7% Over 5 Wks; Quest Down 5%, LabCorp Up 8% in February

UnitedHealth in NY AG Cuomo’s Crosshairs for Reimbursement Fraud